Sehhoon Park
Clinical trials sponsored by Sehhoon Park, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill shows promise against tough lung cancer in early trial Results expected Dec 2026 (estimated)
- New combo therapy targets aggressive lung cancer transformation Results expected Mar 2027 (estimated)
-
New combo therapy targets aggressive lung cancer transformation
Disease control Recruiting nowThis phase 2 trial tests a combination of tarlatamab (a targeted immune therapy), chemotherapy, and atezolizumab in 50 adults whose lung cancer has transformed from a common type (adenocarcinoma) to a more aggressive small cell form after initial treatment. The goal is to see if …
Phase 2 • Sponsor: Sehhoon Park • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New combo tackles Drug-Resistant lung cancer in early trial
Disease control Recruiting nowThis phase 2 trial tests whether combining two targeted drugs—lazertinib and tepotinib—can shrink tumors in people with advanced EGFR-mutant non-small cell lung cancer whose disease has worsened after initial lazertinib treatment due to MET gene changes. About 47 participants wil…
Phase 2 • Sponsor: Sehhoon Park • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC